Cathie's Ark Logo
Fate Therapeutics Inc Logo

ARKK Holdings of Fate Therapeutics (FATE) - Updated Daily

Gene TherapyGenomicsCAR-NK Gene TherapyStem CellsCRSPR Gene Editing
The Bucket Report Icon
Trader's Guide 2024Ships December 21st. Download our December Market Report and reserve your copy today.
Date
Direction
Shares
Fund Weight
Fund
January 10, 2023
SELL1.125k0.0001%ARKK
January 6, 2023
SELL19.096k0.0014%ARKK
January 3, 2023
SELL1.150m0.196%ARKK
December 29, 2022
SELL2.823m0.4897%ARKK
December 28, 2022
SELL142.110k0.0244%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
0%$583.30m
🏋🏿‍♂️Weight Rank In ARKK🌏Country
30🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
216$78.47
🎫ARK Ownership Percent
0%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...